Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-02-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectsubjectsplacebogskmedical
  Phrases that lowered it: therapytreatment withmgstudy treatmentefficacy and
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Sponsor's past trials: 2095 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 5.8% (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 19.5% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 96.6% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 47918 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 7330 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: not given (lowers risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients NCT02555371 · started 2016 · scored riskier than 40% of active trials completed
• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects NCT01691859 · started 2012 · scored riskier than 58% of active trials completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma NCT01691521 · started 2012 · scored riskier than 19% of active trials completed
• A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects NCT01842607 · started 2013 · scored riskier than 44% of active trials completed
• A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects NCT02135692 · started 2014 · scored riskier than 38% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.